Sven Hoffner Project

The Sven Hoffner Project

Bacteriologist Sven Hoffner has since 2014 a part time position as Senior Research at MTC. He is also working at the Public Health Agency of Sweden, where he is responsible for the WHO Supranational Reference Laboratory for drug resistant TB.

His research project group includes Ass Prof Yi Hu from Fudan University Shanghai and Dr Jim Werngren. The research is focused on Tuberculosis and mycobacteriology, especially drug resistant TB. Various aspects of this, such as development and transmission of drug resistant M tuberculosis strains, mechanism of resistance and the role of molecular tests to detect resistant related mutations indicating clinically relevant drug resistance. Another related area is the activity of new anti-TB compounds, Dr Hoffner’s group were actively involved in the preclinical investigation of Bedaquiline, the first specific TB drug coming to market in 40 years. 

Sven Hoffner is Swedish PI for a major VR project focused on the control of drug resistant TB in China, and was recently appointed an adjunct full professorship at the San Diego State University.


A Multi-Laboratory, Multi-Country Study to Determine Bedaquiline Minimal Inhibitory Concentration Quality Control Ranges for Phenotypic Drug-Susceptibility Testing.
Kaniga K, Cirillo D, Hoffner S, Ismail N, Kaur D, Lounis N, et al
J. Clin. Microbiol. 2016 Sep;():

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
Zignol M, Dean A, Alikhanova N, Andres S, Cabibbe A, Cirillo D, et al
Lancet Infect Dis 2016 Oct;16(10):1185-92

Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
Li D, Hu Y, Werngren J, Mansjö M, Zheng X, Drobniewski F, et al
Antimicrob. Agents Chemother. 2016 Sep;60(9):5159-66

Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Zheng X, Zheng R, Hu Y, Werngren J, Forsman L, Mansjö M, et al
Antimicrob. Agents Chemother. 2016 Aug;60(8):4786-92

Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis.
Gustafsson T, Osman H, Werngren J, Hoffner S, Engman L, Holmgren A
Biochim. Biophys. Acta 2016 Jun;1860(6):1265-71

Populations of latent Mycobacterium tuberculosis lack a cell wall: Isolation, visualization, and whole-genome characterization.
Velayati A, Abeel T, Shea T, Konstantinovich Zhavnerko G, Birren B, Cassell G, et al
Int J Mycobacteriol 2016 Mar;5(1):66-73

Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment.
Hu Y, Zhao Q, Werngren J, Hoffner S, Diwan V, Xu B
BMC Infect. Dis. 2016 Jan;16():4

Molecular Epidemiology of Mycobacterium Tuberculosis Strains in the North-West and West of Iran.
Sahebi L, Ansarin K, Hoffner S, Farajnia S, Seyyedi M, Khalili M, et al
Ann Med Health Sci Res ;5(5):334-9

Beijing clades of Mycobacterium tuberculosis are associated with differential survival in HIV-negative Russian patients.
Balabanova Y, Nikolayevskyy V, Ignatyeva O, Kontsevaya I, Mironova S, Kovalyov A, et al
Infect. Genet. Evol. 2015 Dec;36():517-23

Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study.
Tagliani E, Cabibbe A, Miotto P, Borroni E, Toro J, Mansjö M, et al
J. Clin. Microbiol. 2015 Sep;53(9):2961-9

Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.
Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, et al
J. Antimicrob. Chemother. 2015 Mar;70(3):686-96

Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage.
Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, et al
Nat. Genet. 2015 Mar;47(3):242-9

Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis.
Gonzalo X, Drobniewski F, Hoffner S, Werngren J
J. Antimicrob. Chemother. 2014 Nov;69(11):3001-5

Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.
Miotto P, Cabibbe A, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, et al
MBio 2014 Oct;5(5):e01819-14

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Hameed P S, Patil V, Solapure S, Sharma U, Madhavapeddi P, Raichurkar A, et al
J. Med. Chem. 2014 Jun;57(11):4889-905

In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.
Werngren J, Wijkander M, Perskvist N, Balasubramanian V, Sambandamurthy V, Rodrigues C, et al
Antimicrob. Agents Chemother. 2014 Jul;58(7):4222-3

Comparison between RFLP and MIRU-VNTR genotyping of Mycobacterium tuberculosis strains isolated in Stockholm 2009 to 2011.
Jonsson J, Hoffner S, Berggren I, Bruchfeld J, Ghebremichael S, Pennhag A, et al
PLoS ONE 2014 ;9(4):e95159

Senior researcher

Sven Hoffner

Organizational unit: Sven Hoffner group